Gilead Sciences, Inc. company logo

# RNN 2nd Gen Model Gilead Sciences, Inc. Biological products, except diagnostic

Prediction models:
Subscribe >> Deal exit on
May 17, 2019
Deal entry on
May 17, 2019
0.32%Expected margin
73.58% successful of 53 deals
$ 66.36 Last close price
at 17-may-2019

GILD

Model's trade recommendations -0.90% Return for period

3.13% Annual return

$87.20B Market Cap

β 1.19  

GILD

Model (following trade recommendations)

GILD

Underlying stock

S&P 500

Index
Return for period -0.90%
7.26%
1.78%
52wk return 7.71%
-2.44%
16.82%
52wk Range
60.54—79.00
2000.54—2399.63
Sortino ratio 0.38
Sharpe ratio 0.31
Norm. RMSE 1.13%
Downside risk 9.00%
Volatility 0.00%
  • 2.28 (3.41%) Div (Yield)
  • BUY Analysts consensus recommendation

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.

Industry sector: Medical

Sector classification: Biological products, except diagnostic

Deep Learning based analysis and prediction model for Gilead Sciences, Inc. (GILD) stock is a 2nd Generation Non-linear Autoregressive (NAR) model based on the LSTM/GRU Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 23, 2015.

Market data for GILD model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a regular basis.

Float 1287M
P/E 8.67
Shares Outstanding 1304M
% Held by Insiders 1.30%
% Held by Institutions 78.43%
EPS (last reported FY) $8.56
EPS (last reported Q) $1.37
EPS, estimated (last reported Q) $1.65
Total revenues $26 B
Net income $5 B